Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting

TOKYO, Nov 24, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that the company will have a total of 34 poster presentations, including the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa) at the 76th American Epilepsy Society Annual Meeting (AES 2022), to be […]

Eisai Satisfies All-case Study Requirement for Antiepileptic Agent Inovelon

TOKYO, Nov 2, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has received notification from Japan’s Ministry of Health, Labour, and Welfare (MHLW) that the “all-case study” specified post-marketing observational study condition required at the time of approval of antiepileptic agent Inovelon Tablets 100 mg and 200 mg (rufinamide) […]

Hua Medicine’s Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China

SHANGHAI, CHINA, Oct 10, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration (NMPA) of China on October […]

Claudin18.2, a shining star in gastric cancer, Transcenta’s TST001 stands at the global forefront

HONG KONG, Sep 28, 2022 – (ACN Newswire via SEAPRWire.com) – Transcenta Holding Limited (06628.HK), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announced that interim safety and efficacy data of dose expansion cohort from the phase I/II study of TST001 (Osemitamab), a humanized ADCC-enhanced anti-Claudin18.2 […]

Oculis announces publication and presentation of Phase 2 data showing topical OCS-01 improves macular thickness and visual acuity in patients with diabetic macular edema

LAUSANNE, Switzerland, Sep 6, 2022 – (ACN Newswire via SEAPRWire.com) – Oculis S.A., (‘Oculis’) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, announces that the Phase 2 DX-211, a randomized, double blinded, multi-center and vehicle controlled clinical trial assessing the safety and efficacy of topical OCS-01 […]

Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022

TOKYO, Sep 6, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2022, which is taking place virtually and in-person in Paris, France from September 9 to 13. […]

Zai Lab Announces Second Quarter 2022 Financial Results and Corporate Updates

Key pipeline milestones achieved including the BLA acceptance of efgartigimod by China’s NMPA and positive topline results for the KarXT Phase 3 EMERGENT-2 trial Continued revenue growth led by ZEJULA; strong balance sheet with a cash position of $1.26 billion Company to host a conference call and webcast on August 10, 2022, at 8:00 a.m. […]

HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial

— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase III trial evaluating this combination is underway — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE via SEAPRWire.com) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) […]

HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer

— Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile — — Plans for regulatory submissions underway in the U.S., Europe and Japan — — Results to be submitted to an upcoming medical meeting — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J.,, Aug. 07, 2022 (GLOBE […]

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial

TOKYO and RAHWAY, N.J., Aug 4, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) today announced that the Phase 3 LEAP-002 trial investigating LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, the […]

HUTCHMED Initiates a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE via SEAPRWire.com) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a bridging study of tazemetostat in China. The first patient received their first dose on July 29, 2022. The bridging study is a multicenter, open-label, Phase II […]

HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China

HMPL-A83 is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and its second large molecule drug candidate to enter clinical studies HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 15, 2022 (GLOBE NEWSWIRE via SEAPRWire.com) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a Phase I […]

Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis

Efgartigimod alfa injection is the first accepted BLA submission of an FcRn antagonist for gMG patients in China SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., July 13, 2022 (GLOBE NEWSWIRE via SEAPRWire.com) — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that China’s National Medical Products Administration […]

HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting

— 49% ORR amongst SAVANNAH patients with higher MET levels — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 12, 2022 (GLOBE NEWSWIRE via SEAPRWire.com) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces the first presentation of results from the ongoing SAVANNAH global Phase II trial at the upcoming International Association for the […]